Post Marketing Surveillance Study of Cuprimine
Information source: Merck Sharp & Dohme Corp.
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Scleroderma
Intervention: Cuprimine (penicillamine) (Drug)
Phase: N/A
Status: No longer available
Sponsored by: Merck Sharp & Dohme Corp.
Summary
Cuprimine (penicillamine) was made available in the Philippines by the Sponsor under a
Compassionate Special Permit issued by the Bureau of Food and Drugs. Physicians were able
to request the drug for their patients from the Sponsor. A Clinical Study Report form was
completed for each purchase of Cuprimine.
Clinical Details
Official title: Post Marketing Surveillance Study of Cuprimine (MK-0172-001)
Study design: N/A
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- None
Exclusion Criteria:
- None
Locations and Contacts
Additional Information
Last updated: November 12, 2014
|